Home >> Signaling Pathways >> JAK/STAT Signaling

JAK/STAT Signaling

Targets for  JAK/STAT Signaling

Products for  JAK/STAT Signaling

  1. Cat.No. Product Name Information
  2. GC65572 EGFR Protein Tyrosine Kinase Substrate EGFR Protein Tyrosine Kinase Substrate is a EGFR protein tyrosine kinase substrate. EGFR Protein Tyrosine Kinase Substrate  Chemical Structure
  3. GC64497 EGFR-IN-17 EGFR-IN-17 is a potent and selective inhibitor of the epidermal growth factor receptor ( IC50 0.0002 μM) to overcome C797S-mediated resistance. EGFR-IN-17  Chemical Structure
  4. GC33195 EGFR-IN-2 EGFR-IN-2 is a a noncovalent, irreversible, mutant-selective second generation EGFR inhibitor. EGFR-IN-2  Chemical Structure
  5. GC19132 EGFR-IN-3 EGFR-IN-3 is a third-generation EGFR TKI, with GI50 values of 5 nM (EGFR L858R/T790M), 10 nM (EGFR del19) and 689 nM (EGFR WT), respectively. EGFR-IN-3 has the potential for NSCLC research. EGFR-IN-3  Chemical Structure
  6. GC66428 EGFR-IN-5 EGFR-IN-5 is a EGFR inhibitor with IC50s of 10.4, 1.1, 34, 7.2 nM for EGFR, EGFRL858R, EGFRL858R/T790M, and EGFRL858R/T790M/C797S, respectively. EGFR-IN-5  Chemical Structure
  7. GC68440 EGFR-IN-69 EGFR-IN-69  Chemical Structure
  8. GC35966 EGFR-IN-7 EGFR-IN-7 is a potent, selective and orally active EGFR kinase inhibitor. EGFR-IN-7 has inhibitory effect for for EGFR (WT) and EGFR (mutant C797S/T790M/L858R) with IC50 values of 7.92 nM and 0.218 nM, respectively. EGFR-IN-7 shows anti-tumor activity. EGFR-IN-7 can be used for the research of various cancers. EGFR-IN-7  Chemical Structure
  9. GC65974 EGFR-IN-9 EGFR-IN-9 (Compound 8) is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M). EGFR-IN-9 has antitumor activity. EGFR-IN-9  Chemical Structure
  10. GC33170 ENMD-119 (ENMD 1198) ENMD-119 (ENMD 1198) (IRC-110160), an orally active microtubule destabilizing agent, is a 2-methoxyestradiol analogue with antiproliferative and antiangiogenic activity. ENMD-119 (ENMD 1198) is suitable for inhibiting HIF-1alpha and STAT3 in human HCC cells and leads to reduced tumor growth and vascularization. ENMD-119 (ENMD 1198)  Chemical Structure
  11. GC33048 Epertinib (S-22611) Epertinib (S-22611) (S-22611) is a potent, oral, reversible, and selective tyrosine kinase inhibitor of EGFR, HER2 and HER4, with IC50s of 1.48 nM, 7.15 nM and 2.49 nM, respectively. Epertinib (S-22611) shows potent antitumor activity. Epertinib (S-22611)  Chemical Structure
  12. GC38350 Epertinib hydrochloride Epertinib hydrochloride (S-22611 hydrochloride) is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER2 and HER4, with IC50s of 1.48 nM, 7.15 nM and 2.49 nM, respectively. Epertinib hydrochloride shows potent antitumor activity. Epertinib hydrochloride  Chemical Structure
  13. GC36003 Erlotinib mesylate EGFR inhibitor Erlotinib mesylate  Chemical Structure
  14. GC36016 Eupalinolide K Eupalinolide K, a sesquiterpene lactones compound from Eupatorium lindleyanum, is a STAT3 inhibitor. Eupalinolide K is a Michael reaction acceptor (MRA) . Eupalinolide K  Chemical Structure
  15. GC65992 FGFR2-IN-3 FGFR2-IN-3 is an orally active selective inhibitor of FGFR2. FGFR2-IN-3  Chemical Structure
  16. GC65991 FGFR2-IN-3 hydrochloride FGFR2-IN-3 hydrochloride is an orally active selective inhibitor of FGFR2. FGFR2-IN-3 hydrochloride  Chemical Structure
  17. GC36044 FIIN-3 FIIN-3 is an irreversible inhibitor of FGFR with an IC50 of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. FIIN-3  Chemical Structure
  18. GC16875 FLLL32 STAT3 inhibitor FLLL32  Chemical Structure
  19. GC14144 Fludarabine DNA synthsis inhibitor Fludarabine  Chemical Structure
  20. GC15134 Fludarabine Phosphate (Fludara) Fludarabine (phosphate) is an analogue of adenosine and deoxyadenosine, which is able to compete with dATP for incorporation into DNA and inhibit DNA synthesis. Fludarabine Phosphate (Fludara)  Chemical Structure
  21. GC19408 FM381

    FM-381 is a highly potent and JAK3-selective janus kinase (JAK) inhibitor

    FM381  Chemical Structure
  22. GC38044 Fraxinellone Fraxinellone  Chemical Structure
  23. GC13285 Galiellalactone inhibits IL-6-mediated JAK/STAT signal transduction Galiellalactone  Chemical Structure
  24. GN10696 Garcinone C Garcinone C  Chemical Structure
  25. GN10741 Garcinone D Garcinone D  Chemical Structure
  26. GC32958 GDC-0339 GDC-0339 is a potent, orally bioavailable and well tolerated pan-Pim kinase inhibitor, with Kis of 0.03 nM, 0.1 nM and 0.02 nM for Pim1, Pim2 and Pim3, respectively. GDC-0339 is discovered as a potential treatment of multiple myeloma. GDC-0339  Chemical Structure
  27. GC68378 GDC-4379 GDC-4379  Chemical Structure
  28. GC19509 Gefitinib-based PROTAC 3 A VHL-recruiting PROTAC Gefitinib-based PROTAC 3  Chemical Structure
  29. GC14102 Genistein

    Genistein is an isoflavone belonging to the flavonoid group of compounds and is found in a number of plants.

    Genistein  Chemical Structure
  30. GC12579 GLPG0634 GLPG0634 (GLPG0634) is a selective and orally active JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively. GLPG0634  Chemical Structure
  31. GC17222 GLPG0634 analogue GLPG0634 analogue (Compoun 176) is a broad spectrum JAK inhibitor with IC50 values of <100 nM against JAK1, JAK2 and JAK3. GLPG0634 analogue  Chemical Structure
  32. GC33253 GNE-955 GNE-955 is a potent and orally active pan Pim kinase inhibitor with Kis of 0.018, 0.11, 0.08 nM for Pim1, Pim2, Pim3, respectively. GNE-955  Chemical Structure
  33. GC36174 Golotimod Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod  Chemical Structure
  34. GC36175 Golotimod (TFA) Golotimod (TFA)  Chemical Structure
  35. GC38386 Golotimod hydrochloride Golotimod hydrochloride (SCV 07 hydrochloride), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod hydrochloride  Chemical Structure
  36. GC33041 Gusacitinib (ASN-002) Gusacitinib (ASN-002) (ASN-002) is an orally active and potent dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with IC50 values of 5-46 nM. Gusacitinib (ASN-002) has anti-cancer activity in both solid and hematological tumor types. Gusacitinib (ASN-002)  Chemical Structure
  37. GC12359 Hispidulin Partial positive allosteric modulator at the benzodiazepine receptor Hispidulin  Chemical Structure
  38. GC50343 HJC 0416 hydrochloride STAT3 inhibitor HJC 0416 hydrochloride  Chemical Structure
  39. GC32807 HJC0152 hydrochloride An orally bioavailable inhibitor of STAT3 HJC0152 hydrochloride  Chemical Structure
  40. GC16208 HO-3867 STAT3 inhibitor, selective HO-3867  Chemical Structure
  41. GN10742 Homoharringtonine Homoharringtonine  Chemical Structure
  42. GC67958 HP590 HP590  Chemical Structure
  43. GC33053 HS-10296 hydrochloride Almonertinib (HS-10296) hydrochloride is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. HS-10296 hydrochloride shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC50: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). HS-10296 hydrochloride is used for the research of the non-small cell lung cancer. HS-10296 hydrochloride  Chemical Structure
  44. GC17982 Icotinib EGFR tyrosine kinase inhibitor Icotinib  Chemical Structure
  45. GC64108 Ifidancitinib Ifidancitinib (ATI-50002) is a potent and selective inhibitor of JAK kinases 1/3. Ifidancitinib  Chemical Structure
  46. GC32809 Ilginatinib (NS-018) Ilginatinib (NS-018) (NS-018) is a highly active and orally bioavailable JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM). Ilginatinib (NS-018)  Chemical Structure
  47. GC33037 Ilginatinib hydrochloride (NS-018 hydrochloride) Ilginatinib hydrochloride (NS-018 hydrochloride) (NS-018 hydrochloride) is a highly active and orally bioavailable JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM). Ilginatinib hydrochloride (NS-018 hydrochloride)  Chemical Structure
  48. GC33018 Ilginatinib maleate (NS-018 (maleate)) Ilginatinib maleate (NS-018 (maleate)) (NS-018 maleate) is a highly active and orally bioavailable JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM). Ilginatinib maleate (NS-018 (maleate))  Chemical Structure
  49. GC32862 inS3-54A18 inS3-54A18 is a potent STAT3 inhibitor, with anti-cancer properties. inS3-54A18  Chemical Structure
  50. GC34178 Isocryptotanshinone Isocryptotanshinone  Chemical Structure
  51. GC19204 Itacitinib Itacitinib is a potent and selective inhibitor of JAK1, with >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2; Itacitinib is used in the research of myelofibrosis. Itacitinib  Chemical Structure
  52. GC36351 Itacitinib adipate Itacitinib adipate is an orally bioavailable and selective JAK1 inhibitor which has been tested for efficacy and safety in a phase II trial in myelofibrosis. Itacitinib adipate  Chemical Structure
  53. GC31866 JAK inhibitor 1 JAK inhibitor 1 is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283. JAK inhibitor 1  Chemical Structure
  54. GC31999 JAK-IN-1 JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively. JAK-IN-1  Chemical Structure
  55. GC36366 JAK-IN-10 JAK-IN-10 is a JAK inhibitor. JAK-IN-10  Chemical Structure
  56. GC68000 JAK-IN-23 JAK-IN-23  Chemical Structure
  57. GC65453 JAK-IN-3 JAK-IN-3 (compound 22) is a potent JAK inhibitor, with IC50 values of 3 nM, 5 nM, 34 nM and 70 nM for JAK3, JAK1, TYK2 and JAK2, respectively. JAK-IN-3  Chemical Structure
  58. GC64959 JAK/HDAC-IN-1 JAK/HDAC-IN-1 is a potent JAK2/HDAC dual inhibitor, exhibits antiproliferative and proapoptotic activities in several hematological cell lines. JAK/HDAC-IN-1 shows IC50s of 4 and 2 nM for JAK2 and HDAC, respectively. JAK/HDAC-IN-1  Chemical Structure
  59. GC33036 JAK1-IN-3 JAK1-IN-3 (AZD4205) is a selective JAK1 inhibitor, with an IC50 of 73 nM, weakly inhibits JAK2 (IC50>14.7 μM), and shows little inhibition on JAK3 (IC50>30 μM). JAK1-IN-3  Chemical Structure
  60. GC33258 JAK1-IN-4 JAK1-IN-4 is a potent and selective JAK1 inhibitor, with IC50s of 85 nM, 12.8 μM and >30 μM for JAK1, JAK2, and JAK3, respectively. JAK1-IN-4 inhibits STAT3 phosphorylation in NCI-H 1975 cells (IC50, 227 nM). JAK1-IN-4  Chemical Structure
  61. GC36363 JAK1-IN-7 JAK1-IN-7 (JAK1-IN-7) is a Janus-associated kinase 1 (JAK1) inhibitor extracted from patent WO2018134213A1, Example 63, has an anti-inflammatory effect. JAK1-IN-7  Chemical Structure
  62. GC36364 JAK2-IN-4 JAK2-IN-4 (compound 16h) is a selective JAK2/JAK3 inhibitor, with IC50 values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively. JAK2-IN-4  Chemical Structure
  63. GC65405 JAK2-IN-6 JAK2-IN-6, a multiple-substituted aminothiazole derivative, is a potent and selective JAK2 inhibitor with an IC50 of 22.86 μg/mL. JAK2-IN-6 shows no activity against JAK1 and JAK3. JAK2-IN-6 has anti-proliferative effect against cancer cells. JAK2-IN-6  Chemical Structure
  64. GC36365 JAK3 covalent inhibitor-1 JAK3 covalent inhibitor-1 is a potent and selective janus kinase 3 (JAK3) covalent inhibitor with an IC50 of 11 nM and shows 246-fold selectivity vs other JAKs. JAK3 covalent inhibitor-1  Chemical Structure
  65. GC33046 JAK3-IN-1 JAK3-IN-1 is a potent, selective and orally active JAK3 inhibitor with an IC50 of 4.8 nM. JAK3-IN-1 shows over 180-fold more selective for JAK3 than JAK1 (IC50 of 896 nM) and JAK2 (IC50 of 1050 nM). JAK3-IN-1  Chemical Structure
  66. GC31902 JAK3-IN-6 JAK3-IN-6 is a potent, selective irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nM. JAK3-IN-6  Chemical Structure
  67. GC33382 JAK3-IN-7 JAK3-IN-7 is a potent and selective JAK3 inhibitor extracted from patent WO2011013785A1, has an IC50 of <0.01 μM. JAK3-IN-7  Chemical Structure
  68. GC67690 JBJ-09-063 hydrochloride

    JBJ-09-063 hydrochloride is a mutation selective allosteric EGFR inhibitor

    JBJ-09-063 hydrochloride  Chemical Structure
  69. GC67860 JBJ-09-063 TFA JBJ-09-063 TFA  Chemical Structure
  70. GC65436 JND3229 JND3229 is a reversible EGFRC797S inhibitor with IC50 values of 5.8, 6.8 and 30.5 nM for EGFRL858R/T790M/C797S, EGFRWT and EGFRL858R/T790M, respectively. JND3229 has good anti-proliferative activity and can effectively inhibit tumour growth in vivo. JND3229 can be used in cancer research, especially in non-small cell carcinoma. JND3229  Chemical Structure
  71. GC15731 L002 p300 inhibitor L002  Chemical Structure
  72. GC25559 Lapatinib (GW-572016) Ditosylate Lapatinib (GW-572016) Ditosylate is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib (GW-572016) Ditosylate  Chemical Structure
  73. GC67759 Lapatinib-d4 Lapatinib-d4  Chemical Structure
  74. GC16021 Lavendustin A EGFR tyrosine kinase inhibitor Lavendustin A  Chemical Structure
  75. GC19218 Lazertinib Lazertinib is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generation EGFR tyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer. Lazertinib  Chemical Structure
  76. GC14857 LFM-A13 BTK-specific tyrosine kinase inhibitor LFM-A13  Chemical Structure
  77. GC64372 Lorpucitinib Lorpucitinib is a Gut-Restricted JAK Inhibitor for the research of Inflammatory Bowel Disease. Lorpucitinib  Chemical Structure
  78. GC69410 Lumretuzumab

    Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized monoclonal antibody that targets HER3 (ERBB3) and can be used for cancer research.

    Lumretuzumab  Chemical Structure
  79. GC67706 LY5 LY5  Chemical Structure
  80. GC34138 M-110 M-110 is a highly selective, ATP-competitive inhibitor of PIM kinases with a preference for PIM-3 (IC50=47 nM). M-110 inhibits PIM-1 and PIM-2 with similar IC50s of 2.5 μM. M-110 inhibits the proliferation of prostate cancer cell lines with IC50s of 0.6 to 0.9 μM. M-110  Chemical Structure
  81. GC68304 Margetuximab Margetuximab  Chemical Structure
  82. GC64710 MC-Val-Cit-PAB-Amide-TLR7 agonist 4 MC-Val-Cit-PAB-Amide-TLR7 agonist 4 (example 15) is a HER2-TLR7 and HER2-TLR8 immune agonist conjugate. MC-Val-Cit-PAB-Amide-TLR7 agonist 4  Chemical Structure
  83. GC44213 ML115 Signal transducer and activator of transcription 3 (STAT3) is a cytokine-inducible transcription factor with roles in inflammation and cancer. ML115  Chemical Structure
  84. GC44227 MM-206 MM-206 is an inhibitor of STAT3 (IC50 = 1.16 μM in an SPR-based competitive assay). MM-206  Chemical Structure
  85. GC32789 Mogrol Mogrol is a biometabolite of mogrosides, and acts via inhibition of the ERK1/2 and STAT3 pathways, or reducing CREB activation and activating AMPK signaling. Mogrol  Chemical Structure
  86. GC36646 Momelotinib Mesylate Momelotinib Mesylate (CYT387 Mesylate) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, appr 10-fold selectivity versus JAK3. Momelotinib Mesylate  Chemical Structure
  87. GN10436 Morusin Morusin  Chemical Structure
  88. GC19256 MTX-211 MTX-211 is a dual inhibitor of EGFR and PI3K, used for the treatment of cancer and other diseases. MTX-211  Chemical Structure
  89. GC10250 Mubritinib (TAK 165) Mubritinib (TAK 165) (TAK-165) is a potent and selective EGFR2/HER2 inhibitor with an IC50 of 6 nM. Mubritinib (TAK 165)  Chemical Structure
  90. GC11126 Mutant EGFR inhibitor Selective Mutated EGFR inhibitor Mutant EGFR inhibitor  Chemical Structure
  91. GC36666 Mutated EGFR-IN-1 Mutated EGFR-IN-1 (Osimertinib analog) is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant and T790M resistance mutant. Mutated EGFR-IN-1  Chemical Structure
  92. GC36667 Mutated EGFR-IN-2 Mutated EGFR-IN-2 (compound 91) is a mutant-selective EGFR inhibitor extracted from patent WO2017036263A1, which potently inhibits single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M (IC50=<1nM) and ex19del/T790M), and can suppress activity of single gain-of-function mutant EGFR (including L858R and ex19del) as well. Mutated EGFR-IN-2 shows anti-tumor antivity. Mutated EGFR-IN-2  Chemical Structure
  93. GC11474 Napabucasin STAT3 inhibitor Napabucasin  Chemical Structure
  94. GC33022 Naquotinib (ASP8273) Naquotinib (ASP8273) (ASP8273) is an orally available, mutant-selective and irreversible EGFR inhibitor; with IC50s of 8-33 nM toward EGFR mutants and 230 nM for EGFR. Naquotinib (ASP8273)  Chemical Structure
  95. GC32836 Naquotinib mesylate (ASP8273) Naquotinib mesylate (ASP8273) (ASP8273 mesylate) is an orally available, mutant-selective and irreversible EGFR inhibitor; with IC50s of 8-33 nM toward EGFR mutants and 230 nM for EGFR. Naquotinib mesylate (ASP8273)  Chemical Structure
  96. GC36699 Nazartinib mesylate Nazartinib mesylate (EGF816 mesylate) is a novel, covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min?1 on EGFR(L858R/790M) mutant, respectively. Nazartinib mesylate  Chemical Structure
  97. GC66329 NDI-034858 NDI-034858 is a TYK2 inhibitor, target TYK2 JH2 domain with binding constant Kd of <200 pM. NDI-034858  Chemical Structure
  98. GC10362 Neratinib (HKI-272) Neratinib (HKI-272) (HKI-272) is an orally available, irreversible, highly selective HER2 and EGFR inhibitor with IC50s of 59 nM and 92 nM, respectively. Neratinib (HKI-272)  Chemical Structure
  99. GC13586 Niclosamide Inhibitor of the STAT3 signaling pathway Niclosamide  Chemical Structure
  100. GC44400 Niclosamide (ethanolamine salt) Niclosamide (BAY2353) olamine is an orally active antihelminthic agent used in parasitic infection research. Niclosamide (ethanolamine salt)  Chemical Structure
  101. GC15901 Niclosamide monohydrate agent for the treatment of most tapeworm infections Niclosamide monohydrate  Chemical Structure

Items 101 to 200 of 333 total

per page
  1. 1
  2. 2
  3. 3
  4. 4

Set Descending Direction